MiMedx Group Company Profile (NASDAQ:MDXG)

About MiMedx Group (MDXG)

MiMedx Group logoMiMedx Group, Inc. (MiMedx) is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. The Company operates in the Regenerative Biomaterials business segment, which includes the development, processing and marketing of regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues in the wound care, surgical, sports medicine, ophthalmic and dental market categories. Its biomaterial platform technologies are AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. The Company processes the human amniotic membrane utilizing its PURION Process, to produce an implant. MiMedx is the supplier of amniotic tissue, having supplied over 500,000 allografts.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: MDXG
  • CUSIP: N/A
Key Metrics:
  • Previous Close: $9.10
  • 50 Day Moving Average: $8.38
  • 200 Day Moving Average: $8.68
  • 52-Week Range: $6.64 - $10.02
  • Trailing P/E Ratio: 82.73
  • Foreward P/E Ratio: 25.28
  • P/E Growth: 1.92
  • Market Cap: $964.91M
  • Outstanding Shares: 106,034,000
  • Beta: 0.97
  • Net Margins: 8.75%
  • Return on Equity: 18.18%
  • Return on Assets: 12.64%
  • Current Ratio: 2.56%
  • Quick Ratio: 2.12%

Analyst Ratings

Consensus Ratings for MiMedx Group (NASDAQ:MDXG) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $11.00 (20.88% upside)

Analysts' Ratings History for MiMedx Group (NASDAQ:MDXG)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/3/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$10.00N/AView Rating Details
2/23/2017Needham & Company LLCReiterated RatingBuy$12.00N/AView Rating Details
12/12/2016First AnalysisReiterated RatingHoldN/AView Rating Details
11/7/2016AegisInitiated CoverageBuy$12.00N/AView Rating Details
6/29/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
4/19/2016Lake Street CapitalLower Price TargetBuy$15.00 -> $12.00N/AView Rating Details
1/13/2016Canaccord GenuityReiterated RatingBuy$12.00N/AView Rating Details
10/30/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$10.00N/AView Rating Details
(Data available from 3/25/2015 forward)


Earnings History for MiMedx Group (NASDAQ:MDXG)
Earnings by Quarter for MiMedx Group (NASDAQ:MDXG)
Earnings History by Quarter for MiMedx Group (NASDAQ:MDXG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017Q416$0.08$0.05$71.13 million$69.90 millionViewListenView Earnings Details
10/27/2016Q316$0.06$0.06$63.18 million$64.40 millionViewListenView Earnings Details
7/26/2016Q216$0.07$0.05$56.49 million$57.00 millionViewListenView Earnings Details
4/26/2016Q116$0.05$0.04$54.05 million$53.40 millionViewListenView Earnings Details
2/23/2016Q415$0.06$0.12$51.84 million$51.80 millionViewListenView Earnings Details
10/29/2015Q315$0.06$0.06$48.61 million$49.00 millionViewListenView Earnings Details
7/30/2015Q215$0.04$0.05$45.03 million$45.68 millionViewListenView Earnings Details
4/27/2015Q1$0.03$0.04ViewListenView Earnings Details
2/26/2015Q414$0.03$0.03$38.15 million$39.60 millionViewListenView Earnings Details
10/30/2014Q314$0.02$0.03$33.50 million$33.50 millionViewListenView Earnings Details
4/25/2014Q114($0.02)($0.01)$19.09 million$19.60 millionViewListenView Earnings Details
2/26/2014Q4($0.01)($0.04)$18.31 million$18.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.01)($0.01)$12.94 million$13.52 millionViewListenView Earnings Details
5/1/2013Q1 2013($0.02)($0.02)$11.34 million$11.56 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MiMedx Group (NASDAQ:MDXG)
Current Year EPS Consensus Estimate: $0.30 EPS
Next Year EPS Consensus Estimate: $0.36 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.03$0.05$0.04
Q2 20163$0.02$0.06$0.05
Q3 20163$0.05$0.08$0.07
Q4 20163$0.04$0.08$0.06
Q1 20173$0.04$0.06$0.05
Q2 20172$0.04$0.04$0.04
Q3 20171$0.07$0.07$0.07
Q4 20172$0.08$0.12$0.10
(Data provided by Zacks Investment Research)


Dividend History for MiMedx Group (NASDAQ:MDXG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for MiMedx Group (NASDAQ:MDXG)
Insider Ownership Percentage: 12.30%
Institutional Ownership Percentage: 50.47%
Insider Trades by Quarter for MiMedx Group (NASDAQ:MDXG)
Institutional Ownership by Quarter for MiMedx Group (NASDAQ:MDXG)
Insider Trades by Quarter for MiMedx Group (NASDAQ:MDXG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/6/2016William Charles TaylorInsiderSell20,400$7.55$154,020.00View SEC Filing  
8/1/2016William Charles TaylorInsiderSell29,112$7.55$219,795.60View SEC Filing  
6/16/2016William Charles TaylorCOOSell24,333$7.52$182,984.16View SEC Filing  
5/20/2016Parker H PetitCEOBuy20,000$6.99$139,800.00View SEC Filing  
5/17/2016Parker H PetitCEOBuy30,000$6.82$204,600.00View SEC Filing  
5/13/2016Parker H PetitCEOBuy40,000$6.75$270,000.00View SEC Filing  
5/12/2016Parker H PetitCEOBuy50,000$6.74$337,000.00View SEC Filing  
11/13/2015Charles Robert EvansDirectorBuy10,000$7.84$78,400.00View SEC Filing  
11/10/2015Parker H PetitCEOBuy131,925$7.58$999,991.50View SEC Filing  
10/30/2015Alexandra O. HadenGeneral CounselBuy4,150$7.92$32,868.00View SEC Filing  
5/28/2015Larry W PapasanDirectorSell5,958$10.09$60,116.22View SEC Filing  
5/18/2015William Charles TaylorCOOSell150,000$10.01$1,501,500.00View SEC Filing  
10/31/2014William Charles TaylorCOOSell150,000$10.01$1,501,500.00View SEC Filing  
7/1/2014William Charles TaylorCOOSell150,000$7.50$1,125,000.00View SEC Filing  
1/17/2014Parker PetitCEOSell150,000$8.28$1,242,000.00View SEC Filing  
8/28/2013William Charles TaylorCOOSell9,800$6.15$60,270.00View SEC Filing  
8/7/2013William Charles TaylorCOOSell183,765$6.21$1,141,180.65View SEC Filing  
5/16/2013Steve GorlinDirectorSell30,000$6.46$193,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for MiMedx Group (NASDAQ:MDXG)
Latest Headlines for MiMedx Group (NASDAQ:MDXG)
finance.yahoo.com logoMiMedx To Present At The 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 24 at 6:30 PM
americanbankingnews.com logoMiMedx Group Inc (MDXG) Rating Increased to B at TheStreet
www.americanbankingnews.com - March 22 at 8:13 AM
biz.yahoo.com logoMIMEDX GROUP, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - March 20 at 4:42 PM
americanbankingnews.com logoMiMedx Group Inc (MDXG) Upgraded to B by TheStreet
www.americanbankingnews.com - March 19 at 9:13 PM
finance.yahoo.com logoMiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors
finance.yahoo.com - March 19 at 5:44 PM
biz.yahoo.com logoMIMEDX GROUP, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obl
biz.yahoo.com - March 13 at 6:11 PM
biz.yahoo.com logoMiMedx Group, Inc. Shareholder Call scheduled for 10:30 am ET today
biz.yahoo.com - March 9 at 6:17 PM
us.rd.yahoo.com logoMiMedx To Present At Canaccord's 12th Annual Musculoskeletal Conference
us.rd.yahoo.com - March 8 at 7:13 PM
finance.yahoo.com logoCoverage initiated on MiMedx Group by Piper Jaffray
finance.yahoo.com - March 3 at 6:30 PM
finance.yahoo.com logoMiMedx to Host Shareholder call on March 9, 2017 to present various strategic and tactical initiatives to shareholders
finance.yahoo.com - March 2 at 9:39 AM
us.rd.yahoo.com logoMiMedx Audit Committee Announces Completion Of Its Investigation
us.rd.yahoo.com - March 1 at 11:33 PM
biz.yahoo.com logoMIMEDX GROUP, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 1 at 6:32 PM
finance.yahoo.com logoMIMEDX GROUP, INC. Financials
finance.yahoo.com - February 28 at 6:36 PM
finance.yahoo.com logoEdited Transcript of MDXG earnings conference call or presentation 23-Feb-17 3:30pm GMT
finance.yahoo.com - February 24 at 7:44 PM
nasdaq.com logoNoteworthy Thursday Option Activity: SPLK, MDXG, ZBRA
www.nasdaq.com - February 23 at 6:31 PM
biz.yahoo.com logoMIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
biz.yahoo.com - February 23 at 6:31 PM
biz.yahoo.com logoQ4 2016 MiMedx Group Inc Earnings Release - Before Market Open
biz.yahoo.com - February 23 at 7:47 AM
finance.yahoo.com logoMiMedx Announces 2016 Record Results
finance.yahoo.com - February 23 at 7:47 AM
thestreet.com logoFirst Week of April 21st Options Trading For MiMedx Group - TheStreet.com
www.thestreet.com - February 22 at 11:44 PM
finance.yahoo.com logoMiMedx Announces Release Date for 2016 Full Year Results
finance.yahoo.com - February 16 at 6:04 PM
finance.yahoo.com logoBenefits Of MiMedx dHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement Edition Of Annals of Plastic Surgery
finance.yahoo.com - February 7 at 7:47 PM
streetinsider.com logoMiMedx Group (MDXG) Raise Buyback Plan by $10M - StreetInsider.com
www.streetinsider.com - February 6 at 6:34 PM
us.rd.yahoo.com logoMiMedx Board of Directors Authorizes $10 Million Increase to the Company's Share Repurchase Program
us.rd.yahoo.com - February 6 at 9:58 AM
us.rd.yahoo.com logoMiMedx Comments On FDA Decision Not To Finalize HCT/P Guidance Documents This Year
us.rd.yahoo.com - February 3 at 7:12 PM
us.rd.yahoo.com logo1:24 pm MiMedx Group comments on the FDA's recently published 2017 calendar year guidance agenda
us.rd.yahoo.com - February 3 at 7:12 PM
bizjournals.com logoAtlanta biomedical company MiMedx claims 'outlandish scheme' by employees
www.bizjournals.com - February 2 at 7:19 PM
streetinsider.com logoMiMedx Group (MDXG) Says Study Confirms dHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction - StreetInsider.com
www.streetinsider.com - January 26 at 9:21 PM
finance.yahoo.com logoScientific Study Confirms MiMedx dHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction
finance.yahoo.com - January 24 at 7:14 PM
finance.yahoo.com logo2:10 pm MiMedx Group announces the latest peer-reviewed scientific study of the MiMedx dehydrated human amnion/chorion membrane allografts has been electronically published in the Journal of Cardiology & Cardiovascular Therapy
finance.yahoo.com - January 24 at 7:14 PM
finance.yahoo.com logoFalling Earnings Estimates Signal Weakness Ahead for MiMedx Group (MDXG) - Yahoo Finance
finance.yahoo.com - January 21 at 5:16 AM


Frequently Asked Questions for MiMedx Group (NASDAQ:MDXG)

What is MiMedx Group's stock symbol?

MiMedx Group trades on the NASDAQ under the ticker symbol "MDXG."

How were MiMedx Group's earnings last quarter?

MiMedx Group Inc (NASDAQ:MDXG) announced its quarterly earnings results on Thursday, February, 23rd. The company reported $0.05 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.08 by $0.03. The business had revenue of $69.90 million for the quarter, compared to analyst estimates of $71.13 million. MiMedx Group had a return on equity of 18.18% and a net margin of 8.75%. The company's revenue was up 34.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.07 EPS.

When will MiMedx Group make its next earnings announcement?

MiMedx Group is scheduled to release their next quarterly earnings announcement on Monday, April, 24th 2017.

What guidance has MiMedx Group issued on next quarter's earnings?

MiMedx Group issued an update on its FY17 earnings guidance on Thursday, February, 23rd. The company provided EPS guidance of $0.31-0.33 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.32. The company issued revenue guidance of $302-307 million, compared to the consensus revenue estimate of $304.61 million.

Where is MiMedx Group's stock going? Where will MiMedx Group's stock price be in 2017?

6 brokerages have issued 1-year price objectives for MiMedx Group's stock. Their forecasts range from $9.00 to $12.00. On average, they expect MiMedx Group's stock price to reach $11.00 in the next twelve months.

What are analysts saying about MiMedx Group stock?

Here are some recent quotes from research analysts about MiMedx Group stock:

  • 1. Needham & Company LLC analysts commented, "MDXG’s 4Q16 revenue was below its 1/9/17 preannouncement (due to increased sales returns and allowances reserves as it transitions from using AvKare) while its adjusted EBITDA beat consensus and adjusted EPS missed consensus. Management reiterated its 2017 guidance. Receivables were 86 days at the end of 4Q16, which is down from 89 days at the end of 3Q16; MDXG continues to add staff to improve collections. While MDXG’s revenue growth reached 35% in 4Q16 and 1Q17 revenue guidance implies 30-36% growth, guidance implies only 23-25% for the full year which strikes us as conservative. With the potential for meaningful upside to consensus and shares at a steep discount to peers (2017E EV/sales of 2.7x vs. small/ mid-cap growth peers at 4.7x), we reiterate our Strong Buy rating." (2/23/2017)
  • 2. According to Zacks Investment Research, "MiMedx is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Innovations in Regenerative Biomaterials is the framework behind their mission to give physicians products and tissues to help the body heal itself. Their biomaterial platform technologies include AmnioFix and EpiFix, their tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through their donor program, a mother delivering via full-term Caesarean section birth can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. They process the human amniotic membrane utilizing their proprietary PURION Process, to produce a safe and effective implant. " (2/21/2017)

Are investors shorting MiMedx Group?

MiMedx Group saw a increase in short interest in the month of March. As of March 15th, there was short interest totalling 26,505,439 shares, an increase of 2.0% from the February 28th total of 25,993,978 shares. Based on an average daily volume of 952,930 shares, the days-to-cover ratio is presently 27.8 days. Approximately 26.7% of the shares of the stock are short sold.

Who owns MiMedx Group stock?

MiMedx Group's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock, Inc (10.40%), State Street Corp (2.88%), Senzar Asset Management LLC (1.18%), Disciplined Growth Investors Inc. MN (0.69%), Russell Investments Group Ltd. (0.59%) and Guggenheim Capital LLC (0.36%). Company insiders that own MiMedx Group stock include Alexandra O Haden, Charles Robert Evans, Larry W Papasan, Parker H Petit and William Charles Taylor.

Who sold MiMedx Group stock? Who is selling MiMedx Group stock?

MiMedx Group's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, GSA Capital Partners LLP, Metropolitan Life Insurance Co. NY, Raymond James Financial Services Advisors Inc. and Putnam Investments LLC.

Who bought MiMedx Group stock? Who is buying MiMedx Group stock?

MiMedx Group's stock was bought by a variety of institutional investors in the last quarter, including Senzar Asset Management LLC, Russell Investments Group Ltd., State Street Corp, Millrace Asset Group Inc., Guggenheim Capital LLC, Disciplined Growth Investors Inc. MN, Bayesian Capital Management LP and Cutter & CO Brokerage Inc.. Company insiders that have bought MiMedx Group stock in the last two years include Alexandra O Haden, Charles Robert Evans and Parker H Petit.

How do I buy MiMedx Group stock?

Shares of MiMedx Group can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of MiMedx Group stock cost?

One share of MiMedx Group stock can currently be purchased for approximately $9.10.

MiMedx Group (MDXG) Chart for Saturday, March, 25, 2017

This page was last updated on 3/25/2017 by MarketBeat.com Staff